Podcasts

Articles

Webinars

Peer-Reviewed

Videos

The annual meeting of the American Academy of Ophthalmology includes subspecialty meetings focusing on the cornea, glaucoma, pediatric ophthalmology, oculofacial plastic surgery, refractive surgery, the retina, and uveitis.

AAO: American Academy of Ophthalmology

At the American Academy of Ophthalmology's annual conference, Rona Z. Silkiss, MD, FACS, an oculoplastic surgeon and owner of Silkiss Eye Surgery, dived into how biologic therapies can be used to treat thyroid eye disease and what can be done to ensure patients have access to these treatments.

Dr Rona Silkiss Details the Use of Biologics to Treat Thyroid Eye Disease

Michael N. Cohen, MD, a retinal surgeon at Wills Eye Hospital and Mid Atlantic Retina, describes the differences between wet and dry age-related macular degeneration (AMD) and how gene therapy could help treat the condition in the future.

Dr Michael Cohen Contrasts the Manifestation and Treatment of Wet vs Dry AMD

Results from the pivotal PHOTON and PULSAR trials highlighted the success of 8-mg aflibercept every 12 or 16 weeks in patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).

High-Dose, Extended Duration Aflibercept Injections Benefit Patients With DME, nAMD

Richard C. Allen, MD, PhD, FACS, an oculoplastic surgeon at Texas Children's Hospital and a professor at Baylor College of Medicine, spoke on how oculoplastic surgery in pediatric patients has changed at the American Academy of Ophthalmology's 2022 conference.

Dr Richard Allen Speaks on the Evolution of Oculoplastic Surgery for Children

During a lecture delivered at the American Academy of Ophthalmology (AAO) annual meeting, James Madara, MD, CEO of the American Medical Association, discussed 3 areas in ophthalmology care that required innovation to effectively push care into the 21st century.

In AAO Lecture, AMA CEO Discusses How the Organization Is Addressing Areas of Innovation

Posters presented at AAO 2022 found that family medicine doctors and artificial intelligence (AI) were able to screen patients for diabetic retinopathy (DR) effectively, although false negatives in AI need to be improved.

Family Medicine Doctors, AI Could Be Effective in DR Screening

Posters presented at the American Academy of Ophthalmology 2022 annual meeting show that the treat-and-extend (T&E) regimen was effective in managing neovascular age-related macular degeneration (nAMD), which makes adherence to treatment vital for long-term outcomes.

T&E Regimen, Consistent Adherence Important to Management of nAMD

Advances in imaging and data science are changing the nature of retina practice, and retina specialists need to stay on top of these, said Michael F. Chiang, MD, director of the National Eye Institute (NEI), who also discussed some of the current research the agency is conducting into artificial intelligence (AI) and telemedicine.

Dr Michael Chiang Chronicles the NEI's Research Into AI, Telemedicine in Ophthalmology

Gene therapy can be used to treat retinitis pigmentosa, an inherited eye disease, and there is likely to be an increase in approved gene therapies for ophthalmic conditions, explained Michel Michaelides, MD, FACP, a consultant ophthalmologist and a professor of ophthalmology at the University College London Institute of Ophthalmology's Genetics Department.

Dr Michel Michaelides Dives Into How Gene Therapy Can Treat Retinitis Pigmentosa

The presentation focused on the Protocol AC trial, which considered whether step therapy had an impact on visual outcomes for patients starting on bevacizumab and switching to aflibercept later. 